Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population
Published: 2 February 2023
Abstract
We debate the real necessity of administering these products with unclear long-term effects to at-risk people with autoimmune conditions, as well as to healthy people, at the time of omicron variants.
The developed products with genetic bases are used mainly in high-income countries (the USA, Europe, Australia), and the use of mRNA-based vaccines is predominant [6,7 Variability of the SARS-CoV-2 virus is challenging, and the vaccines cannot effectively reduce virus spread
Currently, the real effectiveness of mRNA vaccines against Omicron variants is unclear and seems to be lower than that obtained with previous variants, even with a fourth dose [9,10]. Indeed, there are studies showing that, after several months following inoculation, the protection against COVID-19 disease obtained with mRNA vaccines almost completely wanes, unless further doses are taken, and this was noticed already at the time of the spreading of the Delta variant Because there are people that have been negatively affected by the COVID-19 vaccinations—as some people have developed conditions including inflammatory cardiomyopathy, such as myocarditis or pericarditis, as well as neurological problems, thrombosis [17,18,19,20,21,22], and other more rare syndromes—
it is possible that repeated boosts increase the occurrence of the mentioned adverse events. Given that Omicron variants appear more infectious but less lethal [23,24], the risk/benefit calculation, as underlined by a recent publication [18], may likely require updating.
Most importantly, inflammatory cardiomyopathy (myocarditis/pericarditis) seems to be among the predominant unwanted side effects of the genetic vaccines
2.2. Risk of Myo/Pericarditis in COVID-19 Infections and COVID-19 Vaccines
Of particular importance are myocarditis and pericarditis, partly because they determine undeniable long-term effects of the adverse event of vaccination. It was not clear immediately after the mass inoculation started that COVID-19 genetic vaccines could be associated with myocarditis/pericarditis and at which frequency.
For the calculation of the risk/benefit ratio, it is crucial to address whether COVID-19 really constitutes, for example, a major risk of myo/pericarditis as compared to the vaccines. An interesting study is worth mentioning: frequency of myo/pericarditis was examined in a longer follow-up period and in a high number of unvaccinated people in Israel who were recovering from COVID-19 disease [64]. Surprisingly, this study did not detect any increased risk of myo/pericarditis in people that had COVID-19. This is interesting because of the high number of people that were analyzed and the longer follow-up compared to the former studies. These findings seem to contradict data from the CDCOne last consideration about the cited papers on vaccine-induced myo/pericarditis is that some of these studies consider only events recorded in hospitals, thus excluding outpatients and underestimating subclinical cases (identified through instrumental/lab tests). Most studies tend to exclude from the count the events occurring in people with previous COVID-19, as the events are attributed to COVID-19.A recent study found a very high risk of myocarditis in young adults, and the authors discuss how booster mandates at universities in the USA are expected to cause net harm in that per each COVID-19 hospitalization prevented, one can forecast at least 18.5 serious adverse events from mRNA vaccines.Lastly, a recent study should still be mentioned for two reasons: frequency of cardiac manifestation and cost of monitoring people after vaccination. This study represents an active although limited survey of young people at school. In this study, after analyzing 4928 students
after the second dose of the mRNA vaccine, the authors found that 17.1% of the students were affected with cardiac abnormalities.4. Possible Mechanisms of COVID-19 mRNA Vaccine-Induced Tissue/Organ Damage and Virus Immune Evasion Strategies
4.1. Spreading and Persistence of the SARS-CoV-2 Spike Protein in the Body
At the beginning of the COVID-19 immunization campaign, many mass media and organs of health services all over the world repeated that the inoculated material would remain in the deltoid muscle, and only for a few days. The perception by the public was that the mRNA is quickly degraded, which does not apply to the modified mRNA used in the COVID-19 vaccines [100,103,106]. Bio-distribution studies, such as in ref. [103], on liposome micro-particles (LNPs) showed that the material does not stop at the inoculation site.
Much more here-
https://www.mdpi.com/2076-0817/12/2/233 The spike protein your body makes from the vax isn't behaving like claimed from Pharma and their government lackeys. It's showing up in autopsies in other organs where it isn't supposed to be.